Background and objectives: Oxidized HDL (oxHDL) may behave as proinflammatory HDL because of reduced antiinflammatory capacity and is considered a risk factor for mortality in patients on maintenance hemodialysis (MHD). The study presented here assessed the effect of oxHDL on protein-energy wasting (PEW) in MHD patients.
P rotein-energy wasting (PEW) is common among patients on maintenance hemodialysis (MHD), and a large amount of evidence indicates that PEW is an important contributor to morbidity and mortality in such patients (1) . By definition, PEW is caused by poor nutritional intake and changes in body composition such as depleted fat tissue and loss of muscle mass, but it can be assessed using biomarkers and anthropometric measurements. Chronic inflammation in patients on MHD is a risk factor for the development and advancement of the PEW state, although factors associated with uremia per se may contribute to PEW (1) .
HDL is known as a "good" lipoprotein, because high levels seem to protect against advancing atherosclerosis by carrying cholesterol away from the arteries and back to the liver. Other important functions may include potent anti-inflammatory activity and prevention of oxidative stress. HDL possesses antioxidant and anti-inflammatory activities in interactions with circulating cells, inhibiting leukocyte and platelet activation and thus exerting further systemic anti-inflammatory actions (2) (3) (4) . These anti-inflammatory effects possibly contribute to protection from cardiovascular events, although how functions other than lipid transport contribute to protection against atherosclerosis remains uncertain.
In the presence of systemic inflammation and oxidative stress, these antioxidant enzymes can be inactivated and HDL can accumulate oxidized lipids and proteins that result in a proinflammatory nature. Under these conditions, the main protein of HDL, apolipoprotein (apo) A1, can be modified by reactive oxygen species. Alterations of HDL by oxidation impair the capacity to promote cholesterol efflux from monocytes and macrophages and may result in a loss of anti-inflammatory effects and a resulting change to a proinflammatory nature (5) . Systemic anti-inflammatory functions may thus diminish in such a state. Kalantar-Zadeh et al. demonstrated that randomly selected patients on MHD with proinflammatory HDL showed significantly more comorbid conditions and lower quality of life as assessed by the SF36 (6). After 30 months, patients with proinflammatory HDL showed significantly worse outcomes than patients with anti-inflammatory HDL (6) . Oxidized HDL (oxHDL) as a proinflammatory HDL cholesterol (HDL-C) is thus thought to represent a risk factor for mortality and morbidity in MHD patients. However, whether oxHDL can predict PEW has been unclear. The study presented here investigated associations between oxHDL, inflammation, and PEW in patients on MHD.
Materials and Methods

Patients
This study was performed using the pooled samples of an ongoing prospective cohort study that recruited 498 MHD outpatients treated at five hemodialysis clinics. Among this pool of 498 patients, those taking lipid-lowering drugs such as statins, fibrate, ezetimibe, ethyl icosapentate, or sevelamer (n ϭ 297) were excluded from the study because we sought to evaluate lipid metabolism. Another 25 patients who did not provide blood samples; had an anticipated life expectancy Ͻ6 months; or had clinical signs of overt infection, acute vasculitis, or liver disease at the time of recruitment were also excluded.
As a result, 176 of 498 patients were enrolled in this prospective study (Table 1) . Participants were outpatients who had been undergoing MHD for Ն6 months and were Ն20 years old. Written informed consent was obtained from all patients. The local ethics committee approved the study protocol.
All patients were managed similarly in terms of medical treatment and medication use (i.e., lipid disorders were managed according to Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines (7)). Patients were also managed similarly in terms of treatment protocols for hemodialysis (e.g., prescription of dialysis dose). Basically, all recruited patients underwent routine conventional bicarbonate hemodialysis 3 times/wk (3 to 4 h/session) using standard high-flux cellulose triacetate, polysulfone, or other dialysis membranes and conventional bicarbonate dialysate. Patients were recommended to maintain a daily protein intake Ͼ1.0 to 1.2 g/kg body weight.
Study Design
This prospective study assessed nutritional status and biomarkers at baseline and again 1 year later. The following clinicopathological factors were recorded at baseline: cause of ESRD, presence of diabetes mellitus (DM), cardiovascular disease (CVD), smoking history, and systolic blood pressure. CVD was defined by medical history, clinical symptoms, or findings of cerebrovascular (stroke) and/or peripheral vascular disease.
A total of 59 patients had DM; 4 of these patients did not present with diabetic nephropathy. One or more CVDs were present in 82 patients. Myocardial infarctions or clinical signs of ischemic heart disease (angina pectoris) were seen in 31 patients. Peripheral artery disease was seen in 45 patients, whereas 14 patients had a history of stroke or cerebral bleeding, 13 patients had a history of valvular disease, and 5 patients had a history of aortic aneurysm. Causes of ESRD were chronic GN (n ϭ 44, 25%), diabetic nephropathy (n ϭ 55, 31%; type 1 DM, n ϭ 3; type 2 DM, n ϭ 52), nephrosclerosis (n ϭ 21, 12%), polycystic kidney disease (n ϭ 14, 8%), other diseases (n ϭ 14, 8%), and unknown (n ϭ 28, 16%). During follow-up, no patients were newly diagnosed with DM. Five patients were taking vitamin C and E supplements.
Nonfasting venous blood samples were drawn before the hemodialysis session on day 3 after the previous hemodialysis session. Samples were drawn measuring routine biochemical parameters, lipid markers, and high-sensitivity C-reactive protein (hsCRP). Sera were separated by centrifugation and maintained at Ϫ80°C until measurement of oxidized LDL (oxLDL) and oxHDL at baseline. During the follow-up period, 15 patients died and 6 patients moved or were transferred to another hospital. Blood samples could not be obtained for five patients. As a result, 150 patients completed the study. Routine biochemical parameters, oxHDL, and hsCRP were reanalyzed and nutritional status was re-estimated 1 year later in these 150 patients.
Forty serum samples from healthy volunteers were obtained to measure levels of oxHDL and the values were compared with those from enrolled subjects.
Assessment of Nutritional Status
Nutritional status in terms of PEW was assessed by subjective global assessment (SGA) and geriatric nutritional risk index (GNRI) (8) . Trained physicians (H.H. and K.T.) fully assessed SGA according to K/DOQI recommendations, scoring four items (weight loss during the past 6 months, anorexia, subcutaneous fat, and muscle mass) on a 7-point Likert scale (9) . GNRI was calculated from serum albumin level, ideal body weight (BW), and dry weight using the following formula:
Ideal BW was calculated using height and an idealized body mass index (BMI) of 22. Actual BMI was calculated as weight/(height) 2 , with weight measured in kilograms and height in meters. To calculate the dialysis dosage, second-generation Kt/V was estimated using the Daugirdas formula (10) . Normalized protein catabolic rate (nPCR) was also calculated (11) .
Biochemical Methods
The immunonephelometric method was used to measure hsCRP, and creatinine, urea, and albumin (bromocresol purple) were determined using routine procedures. HDL-C was analyzed after apoB-containing lipoprotein precipitation by phosphotungstic acid. LDL cholesterol (LDL-C) was determined using the immunonephelometric method. Serum oxLDL levels were measured by ELISA (oxLDL ELISA Kit; Mercodia, Uppsala, Sweden). The sensitivity of oxLDL measurement was 1 mU/L with an intra-assay coefficient of variation (intra-CV) Ͻ 2.5% and interassay coefficient of variation (inter-CV) Ͻ 9.0%. Analysis of oxHDL was performed by ELISA according to the methods described in our previous study (12) . The sensitivity of oxHDL measurement was 1.5 ng/ml, with intra-CV Ͻ 8.2% and inter-CV Ͻ 10%. In 40 sera from healthy volunteers, the normal range of oxHDL was estimated.
Statistical Analyses
Data are presented as mean Ϯ SD or median (range) unless otherwise noted, with values of P Ͻ 0.05 taken to indicate statistical significance. Comparisons between two groups for normally distributed variables were performed using the t test, whereas the Wilcoxon rank-sums test was used for non-normally distributed variables. For nominal variables, Fisher's exact test was used for comparisons between two groups and the 2 test was used for comparisons among more than two groups.
Correlations were calculated by the Spearman rank test (rho) for nonparametric data. The Wilcoxon signed-rank test was used for comparisons in paired samples. Receiver operating characteristic (ROC) curves were created for parameters as predictors of SGA-positive status. Independent associations between one dependent variable and more than two independent variables were assessed using multiple linear or nominal logistic regression analysis. Data were analyzed using JMP version 7.0.2 (SAS Institute, Cary, NC).
Results
oxHDL
Serum oxHDL levels did not display a normal distribution. Mean serum oxHDL was 147.7 Ϯ 48.7 U/ml (median 140.0 U/ml, range 71.8 to 291.3 U/ml) ( Table 2) , which was significantly elevated as compared with the level (mean 65.9 Ϯ 33.4 U/ml) in healthy volunteers (n ϭ 40; mean age 40 Ϯ 10 years; 63% men).
Serum oxHDL levels were not correlated with age (rho Ϫ0.09, P ϭ 0.23), whereas levels were significantly increased in women (163.6 Ϯ 50.7 U/ml) compared with men (140.5 Ϯ 47.7 U/ml, P ϭ 0.002). Positive correlations were identified between oxHDL and Kt/V (rho 0.20, P ϭ 0.005), hemodialysis duration (rho 0.29, P ϭ 0.003), total cholesterol (rho 0.17, P ϭ 0.02), HDL-C (rho 0.38, P Ͻ 0.0001), and oxLDL (rho 0.15, P ϭ 0.04). Inverse correlations were found between oxHDL and both BMI (rho Ϫ0.32, P Ͻ 0.0001) and GNRI (rho Ϫ0.23, P ϭ 0.001). However, no correlations with albumin (rho 0.05, P ϭ 0.48) or hsCRP (rho Ϫ0.10 P ϭ 0.18) were apparent.
Subanalysis using scores of SGA items was performed. Fat and muscle scores of SGA items were significantly associated with GNRI (fat: rho 0.68, P Ͻ 0.0001; muscle: rho 0.42, P Ͻ 0.0001) and BMI (fat: rho 0.75, P Ͻ 0.0001; muscle: rho 0.40, P Ͻ 0.0001). Serum oxHDL levels were significantly correlated with fat (rho Ϫ0.31, P Ͻ 0.0001) and muscle scores (rho Ϫ0.25, P ϭ 0.0007). Associations between oxHDL and SGA items were confirmed by multivariate models adjusted for age, gender, DM state, and log hsCRP (fat: ␤ ϭ Ϫ0.005, SEM ϭ 0.0009, P Ͻ 0.0001, adjusted r 2 ϭ 0.24; muscle: ␤ ϭ Ϫ0.002, SEM ϭ 0.0008, P ϭ 0.001, adjusted r 2 ϭ 0.16).
Association between Nutritional Status and Biomarkers at Baseline
Patients were divided into two groups (SGA positive and SGA negative) to assess associations between nutritional status and biomarkers, including oxHDL (Table 2) . SGA-positive patients were older with lower BMI, GNRI, and nPCR than SGAnegative patients (Table 2) . Albumin levels were decreased in SGA-positive patients, and levels of oxHDL and hsCRP were significantly increased ( Table 2 ). The accuracy of oxHDL in predicting SGA-positive status by the ROC curve was similar to that of hsCRP, but diagnostic accuracy was poor (area under the curve, 0.63).
Associations between SGA-positive state and contributing factors and between GNRI and contributing factors were estimated using multivariate models, revealing oxHDL and hsCRP as independent predictors of SGA-positive status (Table 3) and oxHDL-C, rather than hsCRP, as an independent predictor of decreased GNRI (Table 4) . However, significant associations were not found between oxLDL and SGA-positive state, or between oxLDL and GNRI by multivariate models.
Associations among oxHDL, hsCRP, and Nutritional State
Because inflammation is an important predictor for PEW, the effect of oxHDL as a proinflammatory biomarker concomitant with elevated hsCRP as an inflammatory biomarker on PEW was estimated. Patients were assigned to groups according to median values for oxHDL and hsCRP [high oxHDL and high hsCRP (n ϭ 39); high oxHDL and low hsCRP (n ϭ 49); low oxHDL and high hsCRP (n ϭ 51); or low oxHDL and low hsCRP (n ϭ 37)]. Prevalence of SGA-positive status was significantly increased in the group with high oxHDL and high hsCRP, and GNRI was less pronounced in that group ( Figure  1 ). According to multivariate models, odds ratios for SGApositive status and GNRI in patients with high oxHDL and high hsCRP were increased compared with elevation of either biomarker alone or low oxHDL and low hsCRP (reference) (Figure 2, a and b) . 
Characteristics of Patients Who Died during Follow-Up
The 15 patients who died were older and more malnourished than the remaining patients, whereas levels of oxHDL and hsCRP did not differ statistically between groups (Table 5) .
Prospective Change in oxHDL and Nutritional State
The influence of high oxHDL at baseline and 1 year on nutritional state was estimated in three groups determined according to median oxHDL level at baseline and 1 year: high oxHDL at baseline and 1 year (n ϭ 51); high oxHDL at either baseline or 1 year, but not both (n ϭ 49); and low oxHDL at baseline and 1 year (n ϭ 50). Prevalence of SGA-positive status at 1 year was significantly increased in the group with high oxHDL at both time points (Figure 3a ) and GNRI at 1 year was significantly decreased in that group (Figure 3b) . The change in GNRI at 1 year was greater in the group with high oxHDL at both time points than in the other groups (Figure 3c) .
Among the 22 patients who started lipid-lowering drugs (statins, n ϭ 9; sevelamer, n ϭ 13) during follow-up, oxHDL levels 1 year later were significantly decreased (statins, 103.6 Ϯ 24.6 U/ml at baseline, 80.3 Ϯ 17.1 U/ml 1 year later, P ϭ 0.04; sevelamer 162.0 Ϯ 48.6 U/ml at baseline, 85.1 Ϯ 26.3 U/ml 1 year later, P ϭ 0.0002).
Discussion
The study presented here demonstrated the effect of oxHDL on PEW in prevalent MHD patients by directly measuring oxHDL. High levels of oxHDL with high hsCRP are associated with high prevalence of PEW.
oxHDL correlated with HDL-C and oxLDL in this study. Increased levels of HDL have been shown to protect against atherosclerosis and systemic inflammation in in vivo and in vitro studies (12) . Moreover, levels of C-reactive protein are elevated in familial hypoalphalipoproteinemia and are more elevated in patients with documented coronary artery disease than in those without the disease, suggesting that normal HDL is anti-inflammatory (13) . However, elevated HDL is not always protective, suggesting that not all HDL functions to prevent atherosclerosis (14) . Dysfunctional HDL with fewer anti- Figure 1 . Association between oxHDL and hsCRP for decreasing GNRI and high score for SGA-positive status. Patients were assigned to groups according to median values for oxHDL and hsCRP as follows: high oxHDL and high hsCRP (n ϭ 39), high oxHDL and low hsCRP (n ϭ 49), low oxHDL and high hsCRP (n ϭ 51), and low oxHDL and low hsCRP (n ϭ 37). The group with high oxHDL and high hsCRP was associated with (a) increased prevalence of SGA and (b) decreased GNRI. inflammatory effects is thus potentially harmful. Qualitative abnormalities of HDL function in MHD patients have been reported in an in vitro study by Morena et al., with reductions in HDL protective capacity against oxidative stress, potentially causing impairment of LDL oxidation prevention and reverse cholesterol transport by HDL in these patients, which may contribute to the accelerated development of atherosclerosis in MHD patients (15) . As a result, oxidative modification of LDL in patients on MHD is associated with oxHDL-C.
Associations between nutritional state and oxHDL in patients on MHD were analyzed by Kalantar-Zadeh; proinflammatory HDL status might be associated with a higher body fat percentage and high BMI levels, suggesting good nutritional state (6) . Conversely, oxHDL was inversely correlated with BMI, GNRI, and fat and muscle scores of SGA items; oxHDL was increased in SGA-positive patients in the study presented here (Table 2) . Although one reason for conflicting findings might be the different methodologies, different body compositions of participants between studies might have led to inconsistent findings. Participant BMI levels in the study presented here were obviously lower than in the study by Kalantar-Zadeh. Several reports have suggested that fat mass is associated with chronic inflammation and oxidative stress in ESRD patients (16) , with a significantly higher truncal fat mass observed in ESRD patients with inflammation (17) and PEW seeming to develop in overweight patients, particularly those with inflammation (18) . Moreover, myeloperoxidase (MPO) is preferentially associated with HDL, causing oxidative damage to apoA1 (14, 19) , and serum levels of MPO correlated positively with BMI and body fat mass (20) . On the other hand, a study confirming the association between nutritional state and oxidative stress demonstrated aggravated oxidative stress in PEW patients with low BMI (21) . Moreover, levels of oxidized ␣1-antitrypsin, a potential marker of activated neutrophil-associated oxidation includ- ing MPO-catalyzed hypochlorous acid production, seems to be increased in MHD patients with low BMI levels and associated with decreases in GNRI (22) . oxHDL may therefore not always be increased in patients with increased fat mass with concomitant oxidative stress but could appear in MHD patients with low BMI and decreased fat. Because chronic inflammation and state of oxidative stress are commonly sustained forms of protein damage in patients on MHD (23, 24) , increased oxHDL as dysfunctional HDL might enhance PEW in MHD patients and might be involved in malnutrition-inflammation-atherosclerosis syndrome (25) . This study demonstrated that the accuracy of oxHDL in predicting PEW was similar to that of hsCRP as estimated by the area under the curve of the ROC curve and showed synergistic effects of oxHDL and hsCRP levels (Figures 1 and 2 ). Whereas C-reactive protein is considered a reliable biomarker of PEW in ESRD patients (26) , diminished anti-inflammatory HDL function (i.e., increased oxHDL) may represent an important risk factor for PEW.
In the study presented here, oxHDL levels were estimated by ELISA using monoclonal antibody to oxidized apoA1 by hydrogen peroxide reacting with oxHDL, but not with native HDL (27) . Ueda et al. measured oxHDL levels in patients who were under high oxidative stress conditions using the same ELISA (27) and found that oxHDL levels in diabetes patients (mean 89.6 Ϯ 61.1 U/ml) and patients with inflammatory diseases such as bacterial or viral infection (mean 110.8 Ϯ 34.6 U/ml) were greater than in normal subjects but lower than in patients on MHD in the study presented here ( Table 2) . As mentioned above, MPO, one of the important sources of oxidative stress in MHD patients, preferentially associates with HDL and causes oxidative damage to apoA1 by hydrogen peroxide oxidation (14, 19) . This antibody thus appears suitable for estimating oxHDL as a proinflammatory factor in such patients. However, we are unable to determine by ELISA the degree to which the anti-inflammatory capacity of HDL is altered by oxidation. In addition, in-depth analysis of oxHDL in a HDL subpopulation is required because small, dense HDL3 with enrichment by apoA1 may represent a key component of antioxidative activity (28 -30) .
This study showed several limitations. First, the findings were only applicable for prevalent MHD patients in the selected group and were potentially affected by the limited study design. In addition, we could not clarify the effects of lipidlowering drugs on oxHDL for this reason. Second, nonfasting venous blood samples were used in this study because nonfasting cholesterol (r 2 ϭ 0.996) and HDL-C (r 2 ϭ 0.984) values in MHD patients were nearly identical, regardless of whether the patient was fasting (31) . However, lipid levels might have been affected slightly by nonfasting status. Third, we could not identify any association between oxHDL and a quantitative measurement of PEW. A large prospective cohort study using the body composition measuring instrument is thus required to clarify the reliability of oxHDL values in predicting PEW in patients on MHD.
In conclusion, oxHDL seems to represent a useful biomarker for estimating PEW in patients on MHD.
